摘要
目的研究多囊卵巢综合征患者实施利拉鲁肽辅助治疗的临床疗效。方法选取66例多囊卵巢综合征患者,根据随机数字表法分为对照组与研究组,各33例。对照组采用二甲双胍治疗,研究组在对照组基础上增加利拉鲁肽辅助治疗,比较两组临床疗效。结果治疗前,两组空腹血糖、餐后2 h血糖及胰岛素抵抗指数指标比较,差异无统计学意义(P>0.05);治疗后,研究组空腹血糖、餐后2 h血糖及胰岛素抵抗指数指标均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组体质量指数及腰围比较,差异无统计学意义(P>0.05);治疗后,研究组体质量指数及腰围均低于对照组,差异有统计学意义(P<0.05)。治疗前,两组抗苗勒管激素、促黄体生成素、睾酮及卵泡刺激素水平比较,差异无统计学意义(P>0.05);治疗后,研究组抗苗勒管激素、促黄体生成素、睾酮及卵泡刺激素水平均低于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为12.12%,对照组为15.15%,对比差异无统计学意义(P>0.05)。结论利拉鲁肽辅助治疗多囊卵巢综合征患者可改善胰岛功能,降低体重,缩小腰围,改善性激素,临床价值显著。
Objective To study the clinical efficacy of liraglutide adjuvant therapy in patients with polycystic ovary syndrome.Methods 66 patients with polycystic ovary syndrome were randomly divided into control group and study group,33 cases in each group.The control group was treated with metformin,and the study group was treated with liraglutide on the basis of the control group.The clinical efficacy of the two groups was compared.Results Before treatment,there were no significant differences in fasting blood glucose,2 h postprandial blood glucose and insulin resistance index between the two groups(P>0.05).After treatment,fasting blood glucose,2 h postprandial blood glucose and insulin resistance index in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in body mass index and waist circumference between the two groups(P>0.05).After treatment,the body mass index and waist circumference of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of anti-mullerian hormone,luteinizing hormone,testosterone and follicle stimulating hormone between the two groups(P>0.05).After treatment,the levels of anti-mullerian hormone,luteinizing hormone,testosterone and follicle stimulating hormone in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions was 12.12%in the study group and 15.15%in the control group,and the difference was not statistically significant(P>0.05).Conclusion The adjuvant treatment of liraglutide in patients with polycystic ovary syndrome can improve islet function,reduce body weight,reduce waist circumference,and improve sex hormone,which has significant clinical value.
作者
梁爽
Liang Shuang(Department of Obstetrics and Gynecology,Meihekou Central Hospital of Jilin Province,Meihekou 135000,China)
出处
《实用妇科内分泌电子杂志》
2021年第31期45-48,共4页
Electronic Journal of Practical Gynecological Endocrinology
关键词
利拉鲁肽
辅助治疗
多囊卵巢综合征
临床疗效
Liraglutide
Adjuvant therapy
Polycystic ovary syndrome
Clinical curative effect
